Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
72 participants
INTERVENTIONAL
2022-06-30
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dual-chamber Patient-controlled Analgesia for Postoperative Recovery
NCT07051109
Opioid-free Anesthesia in Gynecologic Surgery
NCT04700761
the Effect of Opioid-free General Anesthesia
NCT04409964
Role of Curarization During Anesthesia for Gynecologic Surgical Laparotomy Procedures
NCT03519724
Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery
NCT03292965
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dual group
The two drugs are administered separately.
Fentanyl selector
Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
Ketorolac continuous
Continuous (2 ml/hr): Ketorolac 180 mg + N/S 94 ml = total 100 ml
Single group
One drug is administered alone.
Fentanyl selector
Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
Fentanyl continuous
Continuous (2 ml/hr): fentanyl 700 mcg + N/S 86 ml = total 100 ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fentanyl selector
Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
Fentanyl continuous
Continuous (2 ml/hr): fentanyl 700 mcg + N/S 86 ml = total 100 ml
Ketorolac continuous
Continuous (2 ml/hr): Ketorolac 180 mg + N/S 94 ml = total 100 ml
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients scheduled for gynecological laparoscopic surgery under general anesthesia
* Patients who applied for the use of IV-PCA after surgery
Exclusion Criteria
* Patients with hypersensitivity to aspirin or non-steroid anti-inflammatory drugs
* Patients with alcohol or drug dependence
* Patients with peptic ulcers, patients with gastrointestinal bleeding
* Patients with suspected cerebrovascular hemorrhage, organic disorders, or damage to the head related to increased intracranial pressure
* Symptoms of bronchial asthma or bronchospasm
* Patients with severe respiratory depression
* Moderate to severe renal impairment
* Patients with reduced blood volume or dehydration
* polyps in the nose
* angioedema
* Patients with or a history of the convulsive disease
* Patients for whom the use of neuromuscular blocking agents is contraindicated
20 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Bundang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyo-Seok Na
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National Univ. Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B-2110-716-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.